3,4-Methylenedioxymethamphetamine (MDMA), but not morphine, alters APP processing in the rat brain
Kalman J, Bjelik A, Hugyecz M, Timar J, Gyarmati Z, Zana M,
Furst Z, Janka Z, Rakonczay Z, Horvath Z, Pakaski M.
Department of Psychiatry and Alzheimer's Disease Research Centre,
Albert Szent-Gyorgyi Center for Medical and Pharmaceutical Sciences,
Faculty of Medicine, University of Szeged, Szeged, Hungary.
Int J Neuropsychopharmacol. 2006 Feb 17;:1-8
ABSTRACTThe abuse of drugs such as opioids and 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') can have detrimental effects on the cognitive functions, but the exact molecular mechanism whereby these drugs promote neurodegeneration remains to be elucidated. The major purpose of the present pilot study was to determine whether the chronic in-vivo administration of morphine (10 mg/kg) or MDMA (1 mg/kg) to rats can alter the expression and processing of amyloid precursor protein (APP), the central molecule in the proposed pathomechanism of Alzheimer's disease. MDMA treatment significantly decreased the production of APP in the cytosolic fraction of the brain cortex. A concomitant 25% increase was found both in the beta-secretase (BACE) and APP mRNA levels (108%). In contrast, in the applied single dosage chronic morphine treatment did not influence either the APP and BACE protein levels or the APP mRNA production. These results indicate that the chronic use of 'ecstasy', but not morphine, may be harmful via a novel mode of action, i.e. by altering the APP expression and processing in the brain.Club drugs
Deaths in New York
Toxic metabolites of MDMA?
MDMA and sympathetic activity
Ecstasy, cognition and the stereotype threat
Impaired recognition of sadness and disgust?
A toxic intraneuronal metabolite of serotonin?
Electrophysiological evidence of 5-HT damage
Non-neurotoxic and neurotoxic serotonin-releasers
Ecstasy-induced toxicity and the dopamine transporter
5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine